milmedВоенная медицинаMilitary Medicine2074-5044Белорусский государственный медицинский университет10.51922/2074-5044.2022.3.71milmed-1056Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПациенты с сахарным диабетом и артериальной гипертензией в период пандемии COVID-19: медикаментозные возможности улучшения прогнозаPatients with diabetes and hypertension in a time of COVID-19 pandemic: medical opportunities to improve prognosisБоваА. А.BovaA. A.ГромоваЮ. М.GromovaY. M.НехайчикТ. А.NekhajchikT. A.Кафедра военно-полевой терапии Военно-медицинского института в УО «БГМУ»Belarus202205112026037180Copyright © Бова А.А., Громова Ю.М., Нехайчик Т.А., 20262026Бова А.А., Громова Ю.М., Нехайчик Т.А.Bova A.A., Gromova Y.M., Nekhajchik T.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://milmed.ejournal.by/jour/article/view/1056

В статье рассматриваются особенности применения различных классов антигипертензивных препаратов у пациентов с сахарным диабетом, приведены результаты исследований влияния основных групп препаратов на риск инфицирования SARS-Cov-2 и течение инфекции. Особое внимание уделено вопросам стратификации и коррекции сердечно-сосудистого риска при сахарном диабете, безопасности применения статинов у пациентов с COVID-19 и роли фиксированных комбинаций, включая полипилл, в повышении приверженности к лечению для снижения сердечнососудистого риска в период пандемии.

The article considers the peculiarities of the use of different classes of antihypertensive medications in patients with diabetes mellitus, presents the results of studies of the influence of the main classes of blood pressure medications on the risk of SARS-Cov-2 infection and the severity of the course of COVID-19. Particular attention is paid to the stratification and correction of cardiovascular risk in diabetics, the safety of statins in patients with COVID-19 and the role of fixed combinations, including polypill, in increasing adherence to treatment to reduce cardiovascular risk during a pandemic.

COVID-19артериальная гипертензиясахарный диабетсердечно-сосудистый рискгипотензивные препаратыстатиныфиксированные комбинацииCOVID-19arterial hypertensiondiabetes mellituscardiovascular riskantihypertensive medicationsstatinsfixed combinationsReferencesКардиоваскулярные риски у пациентов с сахарным диабетом: современные возможности улучшения прогноза. Руководство для врачей / А. А. Бова [и др.]. – Минск: НиктаГрафиксПлюс. – 2020. – 188 с.Kardiovaskulyarnye riski u pacientov s saharnym diabetom: sovremennye vozmozhnosti uluchsheniya prognoza. Rukovodstvo dlya vrachej / A. A. Bova [i dr.]. – Minsk: NiktaGrafiksPlyus. – 2020. – 188 s.Клинические рекомендации РКО Артериальная гипертензия у взрослых, 2020. – 136 с.Klinicheskie rekomendacii RKO Arterial‘naya gipertenziya u vzroslyh, 2020. – 136 s.Олейников В. Э., И. В. Авдеева, Н. В. Бурко и др. Статины во время пандемии COVID-19: новое прочтение легендарной саги. Атеросклероз и дислипидемии. 2021. – № 3. – С. 5–13.Olejnikov V. E., I. V. Avdeeva, N. V. Burko i dr. Statiny vo vremya pandemii COVID-19: novoe prochtenie legendarnoj sagi. Ateroskleroz i dislipidemii. 2021. – № 3. – S. 5–13.Чазова И. Е., Аксенова А. В., Жернакова Ю. В. Концепция «полипилл» в современной кардиологии. Системные гипертензии. 2018. – Том 15. – № 4. – С. 6–7.Chazova I. E., Aksenova A. V., Zhernakova Yu. V. Koncepciya «polipill» v sovremennoj kardiologii. Sistemnye gipertenzii. 2018. – Tom 15. – № 4. – S. 6–7.Эволюция сердечно-сосудистых полипиллов: от концепции к реальной защите. Medicine Review (кардиология). – № 2 (45), 2017.Evolyuciya serdechno-sosudistyh polipillov: ot koncepcii k real‘noj zashchite. Medicine Review (kardiologiya). – № 2 (45), 2017.2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, Volume 39, Issue 33, 01 September 2018, Pages 3021–3104, doi.org/10.1093/eurheartj/ehy339.2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal, Volume 39, Issue 33, 01 September 2018, Pages 3021–3104, doi.org/10.1093/eurheartj/ehy339.2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2020) 41, 255323. doi: 10.1093/eurheartj/ehz486.2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal (2020) 41, 255323. doi: 10.1093/eurheartj/ehz486.ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease – preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118-20.ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease – preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118-20.Byrd JB, Bakris G., Jamerson K. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. PMID: 24474031 DOI: 10.1007/s11906-014-0419-yByrd JB, Bakris G., Jamerson K. The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension. PMID: 24474031 DOI: 10.1007/s11906-014-0419-yChowdhury R., Khan H., Heydon E. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013 Oct; 34(38): 2940-8. doi: 10.1093/eurheartj/eht295. Epub 2013 Aug 1.Chowdhury R., Khan H., Heydon E. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013 Oct; 34(38): 2940-8. doi: 10.1093/eurheartj/eht295. Epub 2013 Aug 1.Cohen JB, Hanff TC, Corrales-Medina V. et al. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich). 2020 Oct; 22(10): 1780-1788. doi: 10.1111/jch.14011.Cohen JB, Hanff TC, Corrales-Medina V. et al. Randomized elimination and prolongation of ACE inhibitors and ARBs in coronavirus 2019 (REPLACE COVID) Trial Protocol. J Clin Hypertens (Greenwich). 2020 Oct; 22(10): 1780-1788. doi: 10.1111/jch.14011.European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-onHypertension-(CHT)/News/position-statement-of-the-esc-councilon-hypertension-on-ace-inhibitors-and-ang (16 March 2020).European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-onHypertension-(CHT)/News/position-statement-of-the-esc-councilon-hypertension-on-ace-inhibitors-and-ang (16 March 2020).Floyd CN, Wierzbicki AS. Reorganizing the treatment of cardiovascular disease in response to coronavirus disease 2019; time for the polypill? Curr Opin Cardiol. 2020 Jul; 35(4): 428-433. doi: 10.1097/HCO.0000000000000759.Floyd CN, Wierzbicki AS. Reorganizing the treatment of cardiovascular disease in response to coronavirus disease 2019; time for the polypill? Curr Opin Cardiol. 2020 Jul; 35(4): 428-433. doi: 10.1097/HCO.0000000000000759.Hansson L, Hedner T, Lindholm L. The Captopril Prevention Project (CAPPP) in hypertension– baseline data and current status. Blood Press. 1997 Nov;6(6):365-7. doi: 10.3109/08037059709062096.Hansson L, Hedner T, Lindholm L. The Captopril Prevention Project (CAPPP) in hypertension– baseline data and current status. Blood Press. 1997 Nov;6(6):365-7. doi: 10.3109/08037059709062096.Lopes RD, Scarlatelli Macedo AV, Melo de Barros E Silva PG. et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – The BRACE CORONA Trial. American Heart Journal. – Volume 226, August 2020, P. 49–59.Lopes RD, Scarlatelli Macedo AV, Melo de Barros E Silva PG. et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – The BRACE CORONA Trial. American Heart Journal. – Volume 226, August 2020, P. 49–59.Nilsson PM. ACCORD and Risk-Factor Control in Type 2 Diabetes. N Engl J Med 2010; 362:1575-1585. DOI: 10.1056/NEJMoa1001286.Nilsson PM. ACCORD and Risk-Factor Control in Type 2 Diabetes. N Engl J Med 2010; 362:1575-1585. DOI: 10.1056/NEJMoa1001286.Reynolds HR, Adhikari S., Pulgarin C. et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441- 2448. doi: 10.1056/NEJMoa2008975.Reynolds HR, Adhikari S., Pulgarin C. et al. ReninAngiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020 Jun 18;382(25):2441- 2448. doi: 10.1056/NEJMoa2008975.Rezel-Potts E., Douiri A., Chowienczyk PJ, Gulliford MC. Antihypertensive medications and COVID-19 diagnosis and mortality: Population-based case-control analysis in the UnitedKingdom. Br J Clin Pharmacol. 2021; 87: 4601–4610.Rezel-Potts E., Douiri A., Chowienczyk PJ, Gulliford MC. Antihypertensive medications and COVID-19 diagnosis and mortality: Population-based case-control analysis in the UnitedKingdom. Br J Clin Pharmacol. 2021; 87: 4601–4610.Sever PS, Dahlöf B., Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0.Sever PS, Dahlöf B., Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-thanaverage cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0.Unger T., Borghi C., Charchar F. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension Volume 75, Issue 6, June 2020; Pages 1334-1357. doi.org/10.1161/HYPERTENSIONAHA.120.15026.Unger T., Borghi C., Charchar F. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension Volume 75, Issue 6, June 2020; Pages 1334-1357. doi.org/10.1161/HYPERTENSIONAHA.120.15026

The authors declare that there are no conflicts of interest present.